{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T19:27:20Z","timestamp":1793820440722,"version":"4.6.1"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["P30-ESO29067"],"award-info":[{"award-number":["P30-ESO29067"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["RO1-CA289580"],"award-info":[{"award-number":["RO1-CA289580"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["P30-ESO29067"],"award-info":[{"award-number":["P30-ESO29067"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["P30-NCI-CA125123"],"award-info":[{"award-number":["P30-NCI-CA125123"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["U54-CA224076"],"award-info":[{"award-number":["U54-CA224076"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["P30-NCI-CA125123"],"award-info":[{"award-number":["P30-NCI-CA125123"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["U54-CA224076"],"award-info":[{"award-number":["U54-CA224076"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["U54-CA224076"],"award-info":[{"award-number":["U54-CA224076"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["U54-CA224076"],"award-info":[{"award-number":["U54-CA224076"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["P30-NCI-CA125123"],"award-info":[{"award-number":["P30-NCI-CA125123"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["U54-CA224076"],"award-info":[{"award-number":["U54-CA224076"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["P30-NCI-CA125123"],"award-info":[{"award-number":["P30-NCI-CA125123"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["U54-CA224076"],"award-info":[{"award-number":["U54-CA224076"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Syd Kyle Chair Endowment"},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RP220646"],"award-info":[{"award-number":["RP220646"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Ferroptosis is an iron-dependent cell death pathway that involves multiple genes, including the transferrin receptor (TFRC\/CD71), glutathione peroxidase 4 (GPX4) and cystine-glutamate antiporter (SLC7A11). This study is based on the hypothesis that orphan nuclear receptor 4A1 (NR4A1) and NR4A2 maintain low levels of ferroptosis in triple negative breast cancer (TNBC) cells and bis-indole derived (CDIM) compounds act as NR4A1\/2 ligands that induce ferroptosis by enhancing CD71 expression. 1,1-Bis(3\u2032-indolyl)-1-(3,5-disubstitutedphenyl)methane (DIM-3,5) analogs were investigated for their cytotoxicity and effects on NR4A1 and NR4A2 regulated genes and induction of ferroptosis. Several assays also determined enhanced lipoperoxidation, reactive oxygen species and malondialdehyde formation in TNBC cells. Knockdown of NR4A1, NR4A2, Sp1 and Sp4 was carried out by RNA interference. Molecular mechanisms of NR4A1\/2-mediated regulation of CD71 expression were determined using CD71-luciferase promoter constructs, overexpression of Sp1 and chromatin immunoprecipitation (ChIP) assays. Initial studies show that DIM-3,5 analogs act as an inverse NR4A1\/NR4A2 agonists that downregulate the pro-oncogenic responses\/gene products regulated by both receptors in TNBC cells. DIM-3,5 analogs also induced ROS, malondialdehyde and lipoperoxide formation in TNBC cells, and this was accompanied by decreased expression of GPX4 and SLC7A11 and induction of CD71. Induction of CD71, an important biomarker of ferroptosis was observed after treatment of TNBC cells with DIM-3,5 analogs, knockdown of NR4A1, NR4A2, Sp1 or Sp4 demonstrating that induction of CD71 was coregulated by both receptors. Moreover, both promoter and ChIP analysis indicated that NR4A1 and NR4A2 acted as ligand-dependent cofactors of Sp1\/4-mediated expression of CD71 in TNBC cells. Thus, CD71, a key biomarker of ferroptosis is an NR4A1\/2\/Sp regulated gene that can be directly targeted by DIM-3,5 inverse NR4A1\/2 agonists to induce ferroptosis in TNBC cells.<\/jats:p>","DOI":"10.1038\/s41419-025-08143-5","type":"journal-article","created":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T12:34:30Z","timestamp":1762173270000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Orphan nuclear receptor 4A1 (NR4A1) and NR4A2 are endogenous regulators of CD71 and their ligands induce ferroptosis in breast cancer"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2228-457X","authenticated-orcid":false,"given":"Arafat Rahman","family":"Oany","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5236-3485","authenticated-orcid":false,"given":"Srijana","family":"Upadhyay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wai Ning Tiffany","family":"Tsui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8068-3619","authenticated-orcid":false,"given":"Amanuel","family":"Hailemariam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Latka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D.","family":"Landua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7943-8595","authenticated-orcid":false,"given":"Sandra D.","family":"Scherer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alana L.","family":"Welm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo","family":"Villanueva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael T.","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2115-3060","authenticated-orcid":false,"given":"Stephen","family":"Safe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,3]]},"reference":[{"key":"8143_CR1","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1210\/me.2010-0015","volume":"24","author":"MA Pearen","year":"2010","unstructured":"Pearen MA, Muscat GE. Minireview: nuclear hormone receptor 4A signaling: implications for metabolic disease. Mol Endocrinol. 2010;24:1891\u2013903.","journal-title":"Mol Endocrinol"},{"key":"8143_CR2","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1042\/EBC20210004","volume":"65","author":"SC Lith","year":"2021","unstructured":"Lith SC, de Vries CJM. Nuclear receptor Nur77: its role in chronic inflammatory diseases. Essays Biochem. 2021;65:927\u201339.","journal-title":"Essays Biochem"},{"key":"8143_CR3","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1093\/carcin\/bgu157","volume":"35","author":"JR Wang","year":"2014","unstructured":"Wang JR, Gan WJ, Li XM, zhao YY, Li Y, Lu XX, et al. Orphan nuclear receptor Nur77 promotes colorectal cancer invasion and metastasis by regulating MMP-9 and E-cadherin. Carcinogenesis. 2014;35:2474\u201384.","journal-title":"Carcinogenesis"},{"key":"8143_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms4388","volume":"5","author":"F Zhou","year":"2014","unstructured":"Zhou F, Drabsch Y, Dekker TJA, de Vinuesa AG, Li Y, Hawinkels LJAC, et al. Nuclear receptor NR4A1 promotes breast cancer invasion and metastasis by activating TGF-\u03b2 signalling. Nat Commun. 2014;5:3388.","journal-title":"Nat Commun"},{"key":"8143_CR5","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.ygyno.2016.02.030","volume":"141","author":"E Delgado","year":"2016","unstructured":"Delgado E, Boisen MM, Laskey R, Chen R, Song C, Sallit J, et al. High expression of orphan nuclear receptor NR4A1 in a subset of ovarian tumors with worse outcome. Gynecol Oncol. 2016;141:348\u201356.","journal-title":"Gynecol Oncol"},{"key":"8143_CR6","doi-asserted-by":"publisher","first-page":"3265","DOI":"10.1038\/onc.2011.504","volume":"31","author":"SO Lee","year":"2012","unstructured":"Lee SO, Andey T, Jin UH, Kim K, Singh M, Safe S. The nuclear receptor TR3 regulates mTORC1 signaling in lung cancer cells expressing wild-type p53. Oncogene. 2012;31:3265\u201376.","journal-title":"Oncogene"},{"key":"8143_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-024-01834-0","volume":"22","author":"J Liu","year":"2024","unstructured":"Liu J, Wu M, Yang Y, Mei X, Wang L, Wang J, et al. BTN3A1 expressed in cervical cancer cells promotes V\u03b39V\u03b42 T cells exhaustion through upregulating transcription factors NR4A2\/3 downstream of TCR signaling. Cell Commun Signal. 2024;22:459.","journal-title":"Cell Commun Signal"},{"key":"8143_CR8","doi-asserted-by":"publisher","first-page":"6865","DOI":"10.3748\/wjg.v18.i47.6865","volume":"18","author":"YF Han","year":"2012","unstructured":"Han YF. Cao GW. Role of nuclear receptor NR4A2 in gastrointestinal inflammation and cancers. World J Gastroenterol. 2012;18:6865\u201373.","journal-title":"World J Gastroenterol"},{"key":"8143_CR9","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.7314\/APJCP.2013.14.3.2023","volume":"14","author":"J Wang","year":"2013","unstructured":"Wang J, Yang J, Zou Y, Huang GL, He ZW. Orphan nuclear receptor nurr1 as a potential novel marker for progression in human prostate cancer. Asian Pac J Cancer Prev. 2013;14:2023\u20138.","journal-title":"Asian Pac J Cancer Prev"},{"key":"8143_CR10","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.7314\/APJCP.2013.14.5.2805","volume":"14","author":"J Wang","year":"2013","unstructured":"Wang J, Yang J, Li BB, He ZW. High cytoplasmic expression of the orphan nuclear receptor NR4A2 predicts poor survival in nasopharyngeal carcinoma. Asian Pac J Cancer Prev. 2013;14:2805\u20139.","journal-title":"Asian Pac J Cancer Prev"},{"key":"8143_CR11","doi-asserted-by":"publisher","first-page":"3420","DOI":"10.1016\/j.ejca.2013.06.001","volume":"49","author":"Y Han","year":"2013","unstructured":"Han Y, Cai H, Ma L, Ding Y, Tan X, Liu Y, et al. Nuclear orphan receptor NR4A2 confers chemoresistance and predicts unfavorable prognosis of colorectal carcinoma patients who received postoperative chemotherapy. Eur J Cancer. 2013;49:3420\u201330.","journal-title":"Eur J Cancer"},{"key":"8143_CR12","doi-asserted-by":"publisher","first-page":"3436","DOI":"10.1002\/cncr.28228","volume":"119","author":"Y Han","year":"2013","unstructured":"Han Y, Cai H, Ma L, Ding Y, Tan X, Chang W, et al. Expression of orphan nuclear receptor NR4A2 in gastric cancer cells confers chemoresistance and predicts an unfavorable postoperative survival of gastric cancer patients with chemotherapy. Cancer. 2013;119:3436\u201345.","journal-title":"Cancer"},{"key":"8143_CR13","doi-asserted-by":"publisher","first-page":"4337","DOI":"10.62347\/KCPN6689","volume":"14","author":"S Johnson","year":"2024","unstructured":"Johnson S, Yu Z, Li X, Zarei M, Vaziri-Gohar A, Lee M, et al. A novel NR4A2-HuR axis promotes pancreatic cancer growth and tumorigenesis that is inhibited by NR4A2 antagonists. Am J Cancer Res. 2024;14:4337\u201352.","journal-title":"Am J Cancer Res"},{"key":"8143_CR14","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1007\/s10528-022-10216-5","volume":"60","author":"R Abdollahzadeh","year":"2022","unstructured":"Abdollahzadeh R, Azarnezhad A, Paknahad S, Mansoori Y, Pirhoushiaran M, Kanaani K, et al. A proposed TUSC7\/miR-211\/Nurr1 ceRNET might potentially be disturbed by a cer-SNP rs2615499 in breast cancer. Biochem Genet. 2022;60:2200\u201325.","journal-title":"Biochem Genet"},{"key":"8143_CR15","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1158\/1541-7786.MCR-20-0707","volume":"19","author":"S Safe","year":"2021","unstructured":"Safe S, Karki K. The paradoxical roles of orphan nuclear receptor 4A (NR4A) in cancer. Mol Cancer Res. 2021;19:180\u201391.","journal-title":"Mol Cancer Res"},{"key":"8143_CR16","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1210\/me.2014-1102","volume":"28","author":"SO Lee","year":"2014","unstructured":"Lee SO, Li X, Hedrick E, Jin UH, Tjalkens RB, Backos DS, et al. Diindolylmethane analogs bind NR4A1 and are NR4A1 antagonists in colon cancer cells. Mol Endocrinol. 2014;28:1729\u201339.","journal-title":"Mol Endocrinol"},{"key":"8143_CR17","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1124\/jpet.117.246389","volume":"365","author":"SL Hammond","year":"2018","unstructured":"Hammond SL, Popichak KA, Li X, Hunt LG, Richman EH, Damale PU, et al. The Nurr1 ligand,1,1-bis(3\u2019-Indolyl)-1-(p-chlorophenyl)methane, modulates glial reactivity and is neuroprotective in MPTP-induced Parkinsonism. J Pharm Exp Ther. 2018;365:636\u201351.","journal-title":"J Pharm Exp Ther"},{"key":"8143_CR18","doi-asserted-by":"publisher","first-page":"2682","DOI":"10.3390\/cancers13112682","volume":"13","author":"K Karki","year":"2021","unstructured":"Karki K, Mohankumar K, Schoeller A, Martin G, Shrestha R, Safe S. NR4A1 ligands as potent inhibitors of breast cancer cell and tumor growth. Cancers. 2021;13:2682.","journal-title":"Cancers"},{"key":"8143_CR19","doi-asserted-by":"publisher","first-page":"284","DOI":"10.3390\/biom14030284","volume":"14","author":"S Upadhyay","year":"2024","unstructured":"Upadhyay S, Hailemariam AE, Mariyam F, Hafiz Z, Martin G, Kothari J, et al. Bis-indole derivatives as dual nuclear receptor 4A1 (NR4A1) and NR4A2 ligands. Biomolecules. 2024;14:284.","journal-title":"Biomolecules"},{"key":"8143_CR20","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1158\/0008-5472.CAN-19-2314","volume":"80","author":"K Karki","year":"2020","unstructured":"Karki K, Wright GA, Mohankumar K, Jin UH, Zhang XH, Safe S. A bis-indole-derived NR4A1 antagonist induces PD-L1 degradation and enhances antitumor immunity. Cancer Res. 2020;80:1011\u201323.","journal-title":"Cancer Res"},{"key":"8143_CR21","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1038\/s41571-022-00687-1","volume":"19","author":"E Agostinetto","year":"2022","unstructured":"Agostinetto E, Gligorov J, Piccart M. Systemic therapy for early-stage breast cancer: learning from the past to build the future. Nat Rev Clin Oncol. 2022;19:763\u201374.","journal-title":"Nat Rev Clin Oncol"},{"key":"8143_CR22","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1200\/JCO.2007.14.4147","volume":"26","author":"C Liedtke","year":"2008","unstructured":"Liedtke C, Mazouni C, Hess KR, Andr\u00e9 F, Tordai A, Mejia JA, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008;26:1275\u201381.","journal-title":"J Clin Oncol"},{"key":"8143_CR23","doi-asserted-by":"publisher","first-page":"107992","DOI":"10.1016\/j.pharmthera.2021.107992","volume":"232","author":"S Sui","year":"2022","unstructured":"Sui S, Xu S, Pang D. Emerging role of ferroptosis in breast cancer: new dawn for overcoming tumor progression. Pharmacol Ther. 2022;232:107992.","journal-title":"Pharmacol Ther"},{"key":"8143_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2024.101017","volume":"55","author":"B Fu","year":"2024","unstructured":"Fu B, Lou Y, Wu P, Lu X, Xu C. Emerging role of necroptosis, pyroptosis, and ferroptosis in breast cancer: new dawn for overcoming therapy resistance. Neoplasia. 2024;55:101017.","journal-title":"Neoplasia"},{"key":"8143_CR25","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s10549-024-07387-7","volume":"207","author":"K Mokhtarpour","year":"2024","unstructured":"Mokhtarpour K, Razi S, Rezaei N. Ferroptosis as a promising targeted therapy for triple negative breast cancer. Breast Cancer Res Treat. 2024;207:497\u2013513.","journal-title":"Breast Cancer Res Treat"},{"key":"8143_CR26","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/5299218","volume":"2022","author":"S An","year":"2022","unstructured":"An S, Hu M. Quercetin promotes TFEB nuclear translocation and activates lysosomal degradation of ferritin to induce ferroptosis in breast cancer cells. Comput Intell Neurosci. 2022;2022:5299218.","journal-title":"Comput Intell Neurosci"},{"key":"8143_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.820593","volume":"13","author":"J Yin","year":"2022","unstructured":"Yin J, Lin Y, Fang W, Zhang X, Wei J, Hu G, et al. Tetrandrine citrate suppresses breast cancer via depletion of glutathione peroxidase 4 and activation of nuclear receptor coactivator 4-mediated ferritinophagy. Front Pharm. 2022;13:820593.","journal-title":"Front Pharm"},{"key":"8143_CR28","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.3390\/life13081730","volume":"13","author":"A Cruz-Gregorio","year":"2023","unstructured":"Cruz-Gregorio A, Aranda-Rivera AK. Quercetin and ferroptosis. Life. 2023;13:1730.","journal-title":"Life"},{"key":"8143_CR29","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.3390\/nu16081201","volume":"16","author":"D Wendlocha","year":"2024","unstructured":"Wendlocha D, Kubina R, Krzykawski K, Mielczarek-Palacz A. Selected flavonols targeting cell death pathways in cancer therapy: the latest achievements in research on apoptosis, autophagy, necroptosis, pyroptosis, ferroptosis, and cuproptosis. Nutrients. 2024;16:1201.","journal-title":"Nutrients"},{"key":"8143_CR30","doi-asserted-by":"publisher","first-page":"8152","DOI":"10.3390\/ijms24098152","volume":"24","author":"M Lee","year":"2023","unstructured":"Lee M, Upadhyay S, Mariyam F, Martin G, Hailemariam A, Lee K, et al. Flavone and hydroxyflavones are ligands that bind the orphan nuclear receptor 4A1 (NR4A1). Int J Mol Sci. 2023;24:8152.","journal-title":"Int J Mol Sci"},{"key":"8143_CR31","doi-asserted-by":"publisher","first-page":"5280","DOI":"10.3390\/ijms23095280","volume":"23","author":"HS Lee","year":"2022","unstructured":"Lee HS, Kim DH, Lee IS, Park JH, Martin G, Safe S, et al. Plant alkaloid tetrandrine is a nuclear receptor 4A1 antagonist and inhibits Panc-1 cell growth in vitro and in vivo. Int J Mol Sci. 2022;23:5280.","journal-title":"Int J Mol Sci"},{"key":"8143_CR32","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1186\/s13046-021-02199-9","volume":"40","author":"R Shrestha","year":"2021","unstructured":"Shrestha R, Mohankumar K, Martin G, Hailemariam A, Lee S, Jin U, et al. Flavonoids kaempferol and quercetin are nuclear receptor 4A1 (NR4A1, Nur77) ligands and inhibit rhabdomyosarcoma cell and tumor growth. J Exp Clin Cancer Res. 2021;40:392.","journal-title":"J Exp Clin Cancer Res"},{"key":"8143_CR33","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1124\/molpharm.121.000481","volume":"102","author":"L Zhang","year":"2022","unstructured":"Zhang L, Martin G, Mohankumar K, Hampton JT, Liu WR, Safe S. Resveratrol binds nuclear receptor 4A1 (NR4A1) and acts as an NR4A1 antagonist in lung cancer cells. Mol Pharm. 2022;102:80\u201391.","journal-title":"Mol Pharm"},{"key":"8143_CR34","doi-asserted-by":"publisher","first-page":"449","DOI":"10.3390\/ijms24010449","volume":"24","author":"L Rochette","year":"2022","unstructured":"Rochette L, Dogon G, Rigal E, Zeller M, Cottin Y, Vergely C. Lipid peroxidation and iron metabolism: two corner stones in the homeostasis control of ferroptosis. Int J Mol Sci. 2022;24:449.","journal-title":"Int J Mol Sci"},{"key":"8143_CR35","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.18399","volume":"28","author":"K Li","year":"2024","unstructured":"Li K, Fan C, Chen J, Xu X, Lu C, Shao H, et al. Role of oxidative stress-induced ferroptosis in cancer therapy. J Cell Mol Med. 2024;28:e18399.","journal-title":"J Cell Mol Med"},{"key":"8143_CR36","doi-asserted-by":"publisher","first-page":"3411","DOI":"10.1016\/j.celrep.2020.02.049","volume":"30","author":"H Feng","year":"2020","unstructured":"Feng H, Schorpp K, Jin J, Yozwiak CE, Hoffstrom BG, Decker AM, et al. Transferrin receptor is a specific ferroptosis marker. Cell Rep. 2020;30:3411\u201323.e7.","journal-title":"Cell Rep"},{"key":"8143_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-05027-w","volume":"13","author":"L Yi","year":"2022","unstructured":"Yi L, Hu Y, Wu Z, Li Y, Kong M, Kang Z, et al. TFRC upregulation promotes ferroptosis in CVB3 infection via nucleus recruitment of Sp1. Cell Death Dis. 2022;13:592.","journal-title":"Cell Death Dis"},{"key":"8143_CR38","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1677\/JME-08-0103","volume":"41","author":"S Safe","year":"2008","unstructured":"Safe S, Kim K. Non-classical genomic estrogen receptor (ER)\/specificity protein and ER\/activating protein-1 signaling pathways. J Mol Endocrinol. 2008;41:263\u201375.","journal-title":"J Mol Endocrinol"},{"key":"8143_CR39","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1158\/0008-5472.CAN-16-1546","volume":"77","author":"A Lacey","year":"2017","unstructured":"Lacey A, Rodrigues-Hoffman A, Safe S. PAX3-FOXO1A expression in rhabdomyosarcoma is driven by the targetable nuclear receptor NR4A1. Cancer Res. 2017;77:732\u201341.","journal-title":"Cancer Res"},{"key":"8143_CR40","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.1002\/mc.22662","volume":"56","author":"E Hedrick","year":"2017","unstructured":"Hedrick E, Lee SO, Safe S. The nuclear orphan receptor NR4A1 regulates \u03b21-integrin expression in pancreatic and colon cancer cells and can be targeted by NR4A1 antagonists. Mol Carcinog. 2017;56:2066\u201375.","journal-title":"Mol Carcinog"},{"key":"8143_CR41","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1158\/1535-7163.MCT-20-0474","volume":"20","author":"R Shrestha","year":"2021","unstructured":"Shrestha R, Mohankumar K, Jin UH, Martin G, Safe S. The histone methyltransferase gene G9A is regulated by nuclear receptor 4A1 in alveolar Rhabdomyosarcoma cells. Mol Cancer Ther. 2021;20:612\u201322.","journal-title":"Mol Cancer Ther"},{"key":"8143_CR42","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1128\/MCB.00912-15","volume":"36","author":"E Hedrick","year":"2016","unstructured":"Hedrick E, Lee SO, Doddapaneni R, Singh M, Safe S. NR4A1 antagonists inhibit \u03b21-integrin-dependent breast cancer cell migration. Mol Cell Biol. 2016;36:1383\u201394.","journal-title":"Mol Cell Biol"},{"key":"8143_CR43","doi-asserted-by":"publisher","first-page":"3985","DOI":"10.1007\/s00262-023-03530-3","volume":"72","author":"K Mohankumar","year":"2023","unstructured":"Mohankumar K, Wright G, Kumaravel S, Shrestha R, Zhang L, Abdelrahim M, et al. Bis-indole-derived NR4A1 antagonists inhibit colon tumor and splenic growth and T-cell exhaustion. Cancer Immunol Immunother. 2023;72:3985\u201399.","journal-title":"Cancer Immunol Immunother"},{"key":"8143_CR44","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1080\/21541264.2025.2521766","volume":"16","author":"S Safe","year":"2025","unstructured":"Safe S, Oany AR, Tsui WN, Lee M, Srivastava V, Upadhyay S, et al. Orphan nuclear receptor transcription factors as drug targets. Transcription. 2025;16:224\u201360.","journal-title":"Transcription"},{"key":"8143_CR45","doi-asserted-by":"publisher","first-page":"284","DOI":"10.3390\/cancers17020284","volume":"17","author":"S Safe","year":"2025","unstructured":"Safe S, Farkas E, Hailemariam AE, Oany AR, Sivaram G, Tsui WNT. Activation of genes by nuclear receptor\/specificity protein (Sp) interactions in cancer. Cancers. 2025;17:284.","journal-title":"Cancers"},{"key":"8143_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2020.101807","volume":"38","author":"Z Ye","year":"2021","unstructured":"Ye Z, Zhuo Q, Hu Q, Xu X, liu M, Zhang Z, et al. FBW7-NRA41-SCD1 axis synchronously regulates apoptosis and ferroptosis in pancreatic cancer cells. Redox Biol. 2021;38:101807.","journal-title":"Redox Biol"},{"key":"8143_CR47","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1016\/j.cell.2022.06.003","volume":"185","author":"BR Stockwell","year":"2022","unstructured":"Stockwell BR. Ferroptosis turns 10: emerging mechanisms, physiological functions, and therapeutic applications. Cell. 2022;185:2401\u201321.","journal-title":"Cell"},{"key":"8143_CR48","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/s41392-024-01769-5","volume":"9","author":"Q Zhou","year":"2024","unstructured":"Zhou Q, Meng Y, Li D, Yao L, Le J, Liu Y, et al. Ferroptosis in cancer: from molecular mechanisms to therapeutic strategies. Signal Transduct Target Ther. 2024;9:55.","journal-title":"Signal Transduct Target Ther"},{"key":"8143_CR49","doi-asserted-by":"publisher","first-page":"30853","DOI":"10.1074\/jbc.M103339200","volume":"276","author":"E Castro-Rivera","year":"2001","unstructured":"Castro-Rivera E, Samudio I, Safe S. Estrogen regulation of cyclin D1 gene expression in ZR-75 breast cancer cells involves multiple enhancer elements. J Biol Chem. 2001;276:30853\u201361.","journal-title":"J Biol Chem"},{"key":"8143_CR50","doi-asserted-by":"publisher","first-page":"4885","DOI":"10.1158\/0008-5472.CAN-12-4081","volume":"73","author":"X Zhang","year":"2013","unstructured":"Zhang X, Claerhout S, Prat A, Dobrolecki LE, Petrovic I, Lai Q, et al. A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models. Cancer Res. 2013;73:4885\u201397.","journal-title":"Cancer Res"},{"key":"8143_CR51","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/978-1-0716-2193-6_10","volume":"2471","author":"LE Dobrolecki","year":"2022","unstructured":"Dobrolecki LE, Lewis MT. Surgical procedure for implantation of human tumor tissue into the epithelium-free mammary fat pad of immunocompromised mice to generate patient-derived xenografts (PDX). Methods Mol Biol. 2022;2471:195\u2013207.","journal-title":"Methods Mol Biol"},{"key":"8143_CR52","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/s43018-022-00337-6","volume":"3","author":"KP Guillen","year":"2022","unstructured":"Guillen KP, Fujita M, Butterfield AJ, Scherer SD, Bailey MH, Chu Z, et al. A human breast cancer-derived xenograft and organoid platform for drug discovery and precision oncology. Nat Cancer. 2022;3:232\u201350.","journal-title":"Nat Cancer"},{"key":"8143_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.xpro.2023.102402","volume":"4","author":"SD Scherer","year":"2023","unstructured":"Scherer SD, Zhao L, Butterfield AJ, Yang CH, Cortes-Sanchez E, Guillen KP, et al. Breast cancer PDxO cultures for drug discovery and functional precision oncology. STAR Protoc. 2023;4:102402.","journal-title":"STAR Protoc"},{"key":"8143_CR54","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.ygyno.2019.04.678","volume":"154","author":"K Mohankumar","year":"2019","unstructured":"Mohankumar K, Li X, Sridharan S, Karki K, Safe S. Nuclear receptor 4A1 (NR4A1) antagonists induce ROS-dependent inhibition of mTOR signaling in endometrial cancer. Gynecol Oncol. 2019;154:218\u201327.","journal-title":"Gynecol Oncol"},{"key":"8143_CR55","doi-asserted-by":"publisher","first-page":"100009","DOI":"10.1016\/j.molpha.2024.100009","volume":"107","author":"S Upadhyay","year":"2025","unstructured":"Upadhyay S, Lee M, Zhang L, Oany AR, Mikheeva SA, Mikheev AM, et al. Dual nuclear receptor 4A1 (NR4A1\/NR4A2) ligands inhibit glioblastoma growth and target TWIST1. Mol Pharm. 2025;107:100009.","journal-title":"Mol Pharm"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08143-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08143-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08143-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T14:08:54Z","timestamp":1762178934000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08143-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,3]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["8143"],"URL":"https:\/\/doi.org\/10.1038\/s41419-025-08143-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6214709\/v1","asserted-by":"object"}]},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,3]]},"assertion":[{"value":"17 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"University of Utah or Baylor College of Medicine may license the models described herein to for-profit companies, which may result in tangible property royalties. The other authors declare that they have no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The Baylor College of Medicine (BCM) and Texas A&M Institutional Animal Care and Use Committee (IACUC) approved all procedures using live animals. All the procedures used in this study were performed in accordance with the guidelines and regulations and approval of the Texas A&M University Institutional Biosafety Committee (IBC-2020-096).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"776"}}